Search Results for "Drug Interactions"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug Interactions. Results 901 to 910 of 1090 total matches.
Ublituximab (Briumvi) for Relapsing Multiple Sclerosis
The Medical Letter on Drugs and Therapeutics • Mar 06, 2023 (Issue 1671)
, systemic absorption of the drug
from breast milk is expected to be minimal.
DRUG INTERACTIONS ...
The FDA has approved the recombinant chimeric
anti-CD20 antibody ublituximab-xiiy (Briumvi – TG Therapeutics) for IV treatment of adults with
relapsing forms of multiple sclerosis (MS), including
clinically isolated syndrome (initial neurological
episode), relapsing-remitting disease, and active
secondary progressive MS (SPMS). Two other anti-CD20 antibodies, IV ocrelizumab (Ocrevus) and SC
ofatumumab (Kesimpta), are also FDA-approved for
these indications.
Med Lett Drugs Ther. 2023 Mar 6;65(1671):36-8 doi:10.58347/tml.2023.1671c | Show Introduction Hide Introduction
Olodaterol (Striverdi Respimat) for COPD
The Medical Letter on Drugs and Therapeutics • Jan 05, 2015 (Issue 1459)
.
DRUG INTERACTIONS — As with other beta2-agonists,
use of olodaterol with non-potassium-sparing ...
Olodaterol (Striverdi Respimat – Boehringer Ingelheim),
a new inhaled long-acting beta2-agonist, has been
approved by the FDA for once-daily maintenance
treatment of airflow obstruction in patients with
chronic obstructive pulmonary disease (COPD). It is
not approved for treatment of acute exacerbations of
COPD or for treatment of asthma. Olodaterol is the third
long-acting beta2-agonist to be approved by the FDA
for once-daily use; indacaterol (Arcapta Neohaler),
which is available as a single agent, and vilanterol,
which is available only in fixed-dose combinations
with the...
Tildrakizumab (Ilumya) - Another IL-23 Antagonist for Psoriasis
The Medical Letter on Drugs and Therapeutics • Jan 14, 2019 (Issue 1563)
in the general
US population.
DRUG INTERACTIONS — Use of live vaccines should be
avoided in patients being ...
Tildrakizumab-asmn (Ilumya – Sun), an interleukin
(IL)-23 antagonist, has been approved by the FDA for
treatment of adults with moderate to severe plaque
psoriasis who are candidates for systemic therapy or
phototherapy. Tildrakizumab is the second selective
IL-23 antagonist to be approved for this indication;
guselkumab (Tremfya) was the first.
Dupilumab (Dupixent) for Asthma
The Medical Letter on Drugs and Therapeutics • Jan 14, 2019 (Issue 1563)
treated with dupilumab for asthma.
DRUG INTERACTIONS — Use of live vaccines should
be avoided ...
The FDA has approved the subcutaneously injected
monoclonal antibody dupilumab (Dupixent – Sanofi/Regeneron) for add-on maintenance treatment of
patients ≥12 years old with moderate to severe
asthma with an eosinophilic phenotype or with oral
corticosteroid-dependent asthma. Dupilumab was
approved earlier to treat adults with moderate to
severe atopic dermatitis inadequately controlled with
topical therapies.
A New Dihydroergotamine Nasal Spray (Trudhesa) for Migraine
The Medical Letter on Drugs and Therapeutics • Dec 27, 2021 (Issue 1640)
of dihydroergotamine.
DRUG INTERACTIONS — CYP3A4 inhibitors increase
serum concentrations of dihydroergotamine ...
The FDA has approved Trudhesa (Impel Neuropharma),
a new dihydroergotamine nasal spray
product, for acute treatment of migraine with or
without aura in adults. Another dihydroergotamine
nasal spray (Migranal, and generics) has been
available for many years for the same indication.
Ivabradine (Corlanor) for Heart Failure
The Medical Letter on Drugs and Therapeutics • May 25, 2015 (Issue 1469)
while taking ivabradine.
DRUG INTERACTIONS — Ivabradine is a substrate of
CYP3A4; concurrent use ...
The FDA has approved ivabradine (Corlanor – Amgen)
to reduce the risk of hospitalization for worsening heart
failure in adults with stable, symptomatic chronic heart
failure with left ventricular ejection fraction (LVEF) ≤35%
who are in sinus rhythm with a resting heart rate ≥70
beats per minute and who are on maximum tolerated
doses of beta blockers or have a contraindication
to beta blocker use. Ivabradine has been available
internationally for years as Procoralan and Corlentor
for treatment of stable angina and heart failure.
Insulin Degludec/Liraglutide (Xultophy 100/3.6) for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • Sep 11, 2017 (Issue 1529)
relationship has not been established.
DRUG INTERACTIONS — Liraglutide can delay gastric
emptying ...
The FDA has approved Xultophy 100/3.6 (Novo
Nordisk), a fixed-ratio combination of insulin
degludec and the GLP-1 (glucagon-like peptide-1)
receptor agonist liraglutide, for once-daily treatment
of adults with type 2 diabetes inadequately controlled
on basal insulin (<50 units daily) or liraglutide (≤1.8
mg daily).
Lonapegsomatropin (Skytrofa) for Growth Hormone Deficiency
The Medical Letter on Drugs and Therapeutics • Feb 07, 2022 (Issue 1643)
proliferative or severe nonproliferative
diabetic retinopathy.
DRUG INTERACTIONS — Pharmacologic ...
Lonapegsomatropin-tcgd (Skytrofa – Ascendis), a long-acting prodrug of recombinant human growth hormone (rhGH), has been approved by the FDA for
once-weekly subcutaneous (SC) treatment of growth
failure due to inadequate secretion of endogenous
growth hormone in children ≥1 year old who weigh
≥11.5 kg. It is the first once-weekly rhGH product to be
approved in the US; other available rhGH formulations
are administered more frequently.
Once-Weekly or Once-Monthly Subcutaneous Buprenorphine (Brixadi) for Opioid Use Disorder
The Medical Letter on Drugs and Therapeutics • Aug 21, 2023 (Issue 1683)
buprenorphine formulation is preferred.
DRUG INTERACTIONS ― Concurrent use of
benzodiazepines or other CNS ...
The FDA has approved a subcutaneously injected,
extended-release formulation of the mu-opioid
receptor partial agonist and kappa-opioid receptor
antagonist buprenorphine (Brixadi – Braeburn)
for once-weekly or once-monthly treatment of
moderate to severe opioid use disorder. Brixadi is
the second subcutaneously injected buprenorphine
formulation to be approved in the US; Sublocade,
which is administered once monthly, was the first.
Buprenorphine is also available for treatment of
opioid use disorder in sublingual formulations with
and without the opioid antagonist...
Med Lett Drugs Ther. 2023 Aug 21;65(1683):133-5 doi:10.58347/tml.2023.1683c | Show Introduction Hide Introduction
Bupivacaine/Meloxicam (Zynrelef) for Postsurgical Pain
The Medical Letter on Drugs and Therapeutics • Jan 24, 2022 (Issue 1642)
or
obstetrical paracervical block anesthesia.
DRUG INTERACTIONS — Use of additional local
anesthetics within 96 ...
The FDA has approved a fixed-dose combination
of the amide local anesthetic bupivacaine and
the nonsteroidal anti-inflammatory drug (NSAID)
meloxicam as an extended-release (ER) solution
(Zynrelef – Heron) for single-dose, intraoperative,
soft-tissue or periarticular instillation to provide
postsurgical analgesia for up to 72 hours in adults
undergoing foot and ankle, small-to-medium open
abdominal, or lower extremity total joint arthroplasty
surgical procedures.